Inflammatory bowel diseases: An immunological approach;Enfermedad inflamatoria intestinal: Una mirada inmunológica

Revista Medica de Chile

Volumn 136, Issue 3, 2008, Pages 367-375

  Sepúlveda, Sofía E ^a,d   Beltrán, Caroll J ^a,b,d   Peralta, Alexis ^a,d   Rivas, Paola ^a,d   Rojas, Néstor ^a,d   Figueroa, Carolina ^b   Quera, Rodrigo ^b,c   Hermoso, Marcela A ^a,d  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^c CLÍNICA LAS CONDES   (Chile)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

Colitis, ulcerative; Crohn disease; Inflammatory bowel diseases; Nod2 signaling adaptor protein; T lymphocytes, helper inducer

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; INTERLEUKIN DERIVATIVE; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR GATA 3;

CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; ENTERITIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; REVIEW; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; GATA3 TRANSCRIPTION FACTOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKINS; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, GENETIC; TOLL-LIKE RECEPTOR 4;

EID: 44849140274     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. RUSSEL MG, STOCKBRUGGER RW. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol 1996; 31: 417-27.
2. LOFTUS EV JR. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-17.
3. FIGUEROA C, QUERA R, VALENZUELA J, JENSEN B. EN fermedad Inflamatoria Intestinal: Experiencia de dos centros chilenos [Inflammatory bowel disease: Experience of two Chilean centers]. Rev Méd Chile 2005; 133: 1295-304.
4. PODOLSKY DK. Inflammatory bowel disease (1). N Engl J Med 1991; 325: 928-37.
5. FIGUEROA C, PERALTA A, HERRERA L, CASTRO P, GUTIERREZ A, VALENZUELA J ET AL. NOD2/CARD15 and Toll-like 4 receptor gene polymorphism in Chilean patients with inflammatory bowel disease. Eur Cytokine Netw 2006; 17: 125-30.
6. ORTIGOSA L. Concepto actual y aspectos clínicos de la enfermedad de Crohn y la colitis ulcerosa. Colombia Médica 2005; 36: 16-24.
7. GUINDI M, RIDDELL RH. Indeterminate colitis. J Clin Pathol 2004; 57: 1233-44.
8. COOMBES JL, ROBINSON NJ, MALOY KJ, UHLIG HH, POWRIE F. Regulatory T cells and intestinal homeostasis. Immunol Rev 2005; 204: 184-94.
9. INOHARA N, NÚNEZ G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3: 371-82.
10. HECHT G. Innate mechanisms of epithelial host defense: spotlight on intestine. Am J Physiol 1999; 277: C351-8.
11. CUNLIFFE RN, MAHIDA YR. Expression and regulation of antimicrobial peptides in the gastrointestinal tract. J Leukoc Biol 2004; 75: 49-58.
12. MATSUOKA K, INOUE N, SATO T, OKAMOTO S, HISAMATSU T, KISHI Y ET AL. T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut 2004; 53: 1303-8.
13. LIN PW, SIMON PO JR, GEWIRTZ AT, NEISH AS, OUELLETTE AJ, MADARA JL ET AL. Paneth cell cryptidins act in vitro as apical paracrine regulators of the innate inflammatory response. J Biol Chem 2004; 279: 19902-7.
14. WEHKAMP J, HARDER J, WEICHENTHAL M, SCHWAB M, SCHAFFELER E, SCHLEE M ET AL. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004; 53: 1658-64.
15. WEHKAMP J, SALZMAN NH, PORTER E, NUDING S, WEICHENTHAL M, PETRAS RE ET AL. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 2005; 102: 18129-34.
16. TYRER P, FOXWELL AR, CRIPPS AW, APICELLA MA, KYD JM. Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium. Infect Immun 2006; 74: 625-31.
17. SANDERS DS. Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease. J Clin Pathol 2005; 58: 568-72.
18. IWASAKI A, KELSALL BL. Mucosal immunity and inflammation. I. Mucosal dendritic cells: their specialized role in initiating T cell responses. Am J Physiol 1999; 276: G1074-8.
19. NIESS JH, BRAND S, GU X, LANDSMAN L, JUNG S, MCCORMICK BA ET AL. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005; 307: 254-8.
20. LIU Z, LEFRANCOIS L. Intestinal epithelial antigen induces mucosal CD8 T cell tolerance, activation, and inflammatory response. J Immunol 2004; 173: 4324-30.
21. WATANABE N, HANABUCHI S, MARLOIE-PROVOST MA, ANTONENKO S, LIU YJ, SOUMELIS V. Human TSLP promotes CD40 ligand-induced IL-12 production by myeloid dendritic cells but maintains their Th2 priming potential. Blood 2005; 105: 4749-51.
22. RIMOLDI M, CHIEPPA M, SALUCCI V, AVOGADRI F, SONZOGNI A, SAMPIETRO GM ET AL. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005; 6: 507-14.
23. GRIMM MC, PAVLI P. NOD2 mutations and Crohn's disease: are Paneth cells and their antimicrobial peptides the link? Gut 2004; 53: 1558-60.
24. BOUMA G, STROBER W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-33.
25. ALVAREZ-LOBOS M, AROSTEGUI JI, SANS M, TASSIES D, PLAZA S, DELGADO S ET AL. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005; 242: 693-700.
26. GAZOULI M, MANTZARIS G, KOTSINAS A, ZACHARATOS P, PAPALAMBROS E, ARCHIMANDRITIS A ET AL. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 2005; 11: 681-5.
27. DUERR RH, TAYLOR KD, BRANT SR, RIOUX JD, SILVERBERG MS, DALY MJ ET AL. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-3.
28. KULLBERG MC, ANDERSEN JF, GORELICK PL, CASPAR P, SUERBAUM S, FOX JG ET AL. Induction of colitis by a CD4+ T cell clone specific for a bacterial epitope. Proc Natl Acad Sci USA 2003; 100: 15830-5.
29. SARTOR RB. Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 390-407.
30. CHAMBERLIN WM, NASER SA. Integrating theories of the etiology of Crohn's disease. On the etiology of Crohn's disease: questioning the hypotheses. Med Sci Monit 2006; 12: RA27-33.
31. GARCÍA RODRÍGUEZ LA, RUIGOMEZ A, PANES J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 2006; 130: 1588-94.
32. CONTE MP, SCHIPPA S, ZAMBONI I, PENTA M, CHIARINI F, SEGANTI L ET AL. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 2006; 55: 1760-7.
33. FUJINO S, ANDOH A, BAMBA S, OGAWA A, HATA K, ARAKI Y ET AL. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
34. IWAKURA Y, ISHIGAME H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116: 1218-22.
35. SZABO SJ, KIM ST, COSTA GL, ZHANG X, FATHMAN CG, GLIMCHER LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100: 655-69.
36. NEURATH MF, WEIGMANN B, FINOTTO S, GLICKMAN J, NIEUWENHUIS E, IIJIMA H ET AL. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 2002; 195: 1129-43.
37. WEIGMANN B, NEURATH MF. T-bet and mucosal Th1 responses in the gastrointestinal tract. Gut 2002; 51: 301-3.
38. LIGHVANI AA, FRUCHT DM, JANKOVIC D, YAMANE H, ALIBERTI J, HISSONG BD ET AL. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA 2001; 98: 15137-42.
39. CHEN Y, LANGRISH CL, MCKENZIE B, JOYCE-SHAIKH B, STUMHOFER JS, MCCLANAHAN T ET AL. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006; 116: 1317-26.
40. YEN D, CHEUNG J, SCHEERENS H, POULET F, MCCLANAHAN T, MCKENZIE BET AL. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-6.
41. Romagnani S. Regulation of the T cell response. Clin Exp Allergy 2006; 36: 1357-1366.
42. CHAKIR H, WANG H, LEFEBVRE DE, WEBB J, SCOTT FW. T-B et/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods 2003; 278: 157-69.
43. NASTA F, UBALDI V, PACE L, DORIA G, PIOLI C. CYtotoxic T-lymphocyte antigen-4 inhibits GATA-3 but not T-bet mRNA expression during T helper cell differentiation. Immunology 2006; 117: 358-67.
44. KATSUMOTO T, KIMURA M, YAMASHITA M, HOSOKAWA H, HASHIMOTO K, HASEGAWA A ET AL. STAT6-dependent differentiation and production of IL-5 and IL-13 in murine NK2 cells. J Immunol 2004; 173: 4967-75.
45. FUSS IJ, HELLER F, BOIRIVANT M, LEON F, YOSHIDA M, FICHTNER-FEIGL S ET AL. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004; 113: 1490-7.
46. GRUNIG G, WARNOCK M, WAKIL AE, VENKAYYA R, BROMBACHER F, RENNICK DM ET AL. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 2261-3.
47. YAMASHITA M, UKAI-TADENUMA M, KIMURA M, OMORI M, INAMI M, TANIGUCHI M ET AL. Identification of a conserved GATA3 response element upstream proximal from the interleukin-13 gene locus. J Biol Chem 2002; 277: 42399-408.
48. HWANG ES, SZABO SJ, SCHWARTZBERG PL, GLIMCHER LH. T Helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 2005; 307: 430-3.
49. LEE HJ, TAKEMOTO N, KURATA H, KAMOGAWA Y, MIYATAKE S, O'GARRA A ET AL. GATA-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J Exp 2000; 192: 105-15.
50. VERGARA T, COFRÉ P, CIFUENTES S, PULGAR U, PUEBLA C, VELASCO S. PREValencia de marcadores serológicos ANCA y ASCA en una población con colitis ulcerosa. [Presence of antineutrophil cytoplasmic antibodies (ANCA) and anti Saccharomyces cerevisiae antibodies (ASCA) among patients with ulcerative colitis]. Rev Méd Chil 2006; 134: 960-4.